A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
Authors:
- 1 November 2022
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 28 (40) , 3289-3304
Abstract
Background: Some reports have pointed out that calcimimetics agents are effective in the treatment of secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) patients, but there is no detailed description of the advantages and disadvantages of calcimimetics agents of SHPT in CKD patients. We tried to pool the published data to verify the effectiveness of calcimimetics agents and to compare the advantages and disadvantages of cinacalcet compared with control in the treatment of SHPT in CKD patients. Methods: We included eligible studies of published papers from January 1st, 2000 to December 31st, 2020 in Medline, Pubmed and Web of science databases, and the data were extracted for this meta-analysis. Results: Twenty-seven studies were eligible, and all the included studies were randomized controlled trials (RCT) including patients treated with long-term dialysis. The results indicated that calcimimetic agents can reduce the parathyroid hormone (PTH, pg/ml) level (WMD = -178.22, 95% CI: -238.57, -117.86, P < 0.00001), calcium (Ca, mg/dl) level (WMD = -0.71, 95% CI: -0.86, -0.55, P < 0.00001), phosphorus (P, mg/dl) level (WMD = -0.32, 95% CI: -0.55, -0.08, P = 0.008), calcium-phosphorus product level (WMD = -7.73, 95% CI: -9.64, -5.82, P < 0.00001). Calcimimetic agents increased the bone alkaline phosphatase (BSAP, ng/ml) levels and rate of achieving target PTH, and reduced osteocalcin levels and the rate of parathyroidectomy. Calcimimetic agents increased the total adverse events’ rate, the rate of hypocalcemia and gastrointestinal side effects (nausea, vomiting, abdominal pain and diarrhea), but there was no significant difference in serious adverse events between the calcimimetic agent group and control group. Conclusion: Calcimimetic agents can reduce the PTH level, Ca level, P level, calcium-phosphorus product level and do not increase serious adverse events.Keywords
This publication has 36 references indexed in Scilit:
- Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled studyBMC Nephrology, 2013
- Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing DialysisNew England Journal of Medicine, 2012
- Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT studyNephrology Dialysis Transplantation, 2012
- Cinacalcet Hydrochloride Therapy for Secondary Hyperparathyroidism in Hemodialysis PatientsTherapeutic Apheresis and Dialysis, 2011
- Secondary HyperparathyroidismClinical Journal of the American Society of Nephrology, 2011
- A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Participants With CKD Not Receiving DialysisAmerican Journal of Kidney Diseases, 2009
- Cinacalcet HCl and Concurrent Low-dose Vitamin D Improves Treatment of Secondary Hyperparathyroidism in Dialysis Patients Compared with Vitamin D AloneClinical Journal of the American Society of Nephrology, 2008
- Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary HyperparathyroidismTherapeutic Apheresis and Dialysis, 2008
- The OPTIMA StudyClinical Journal of the American Society of Nephrology, 2008
- The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismKidney International, 2003